首页 > 市场调查报告书 > 製药

再生医学

干细胞库市场规模、份额和成长分析（按来源、服务类型、应用和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897671

干细胞库市场规模、份额和成长分析（按来源、服务类型、应用和地区划分）－2026-2033年产业预测

Stem Cell Banking Market Size, Share, and Growth Analysis, By Source (Placental Stem Cells, Adipose Tissue-Derived Stem Cells), By Service Type (Sample Preservation & Storage, Sample Analysis), By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月25日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，干细胞库市场规模将达到 116.5 亿美元，到 2025 年将达到 137.8 亿美元，到 2033 年将达到 528.8 亿美元，在预测期（2026-2033 年）内，复合年增长率为 18.3%。

干细胞库市场经历了显着成长，这主要得益于冷冻保存技术的进步和细胞库的发展。单株抗体的广泛应用和干细胞疗法的引入也是推动这一趋势的重要因素。干细胞应用领域的持续研究，特别是用于治疗神经退化性疾病和心血管疾病的造血干细胞移植，提供了广泛的机会。此外，组织库和生物库在保存成人组织和干细胞以用于各种临床应用方面发挥着至关重要的作用。再生医学领域的创新，例如诱导多功能细胞（iPS细胞），为以往无法治癒的疾病带来了希望。此外，晚育趋势的日益增长促使越来越多的父母从婴儿身上获取干细胞以备将来医疗之需，这凸显了脐带血库的重要性。

干细胞库市场驱动因素

干细胞库市场正经历着向成人干细胞，特别是骨髓和脂肪组织来源干细胞的显着转变。这些来源的干细胞来源丰富，并且在伦理上可以取代胚胎干细胞。此外，微创采集方法的创新，例如骨髓穿刺采集，正在改善患者的整体体验，并提高人们对干细胞库的兴趣和接受度。干细胞库的丰富性、伦理考量以及采集技术的进步共同推动了市场发展，并促进了干细胞库服务的普及和整合。

干细胞库市场限制因素

由于干细胞研究和储存相关的监管环境不断变化，干细胞库市场面临巨大的挑战。儘管各国政府制定了严格的法规来维护安全和伦理标准，但这些要求的复杂性却为干细胞库公司带来了挑战。持续的监管变化和不确定性会阻碍市场成长，因为公司必须灵活应对这些波动。这种动态环境会造成障碍，最终影响市场参与企业的有效运作和创新能力，并进一步加剧他们应对复杂法律规范的困难。

干细胞库市场趋势

干细胞库市场正经历显着成长，这主要得益于造血干细胞移植（HSCT）需求的不断增长。 HSCT越来越多地被用于治疗骨髓恶性肿瘤和某些遗传性疾病。 HSCT手术成功率的不断提高凸显了获取干细胞来源的重要性，无论这些干细胞来自私人干细胞库还是捐赠者登记库。随着消费者和医疗服务提供者对干细胞库益处的认识不断加深，对可靠且易于获取的干细胞方案的需求也随之激增。医疗技术的进步和研究的不断深入进一步推动了这一趋势，预示着该领域拥有蓬勃发展的未来。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Cordlife（Singapore）
Cryo-Cell International（US）
LifeCell International（India）
StemCyte（US）
Global Cord Blood（Hong Kong）
Smart Cells International（UK）
Vita34（Germany）
CryoHoldco（US）
Cellerant Therapeutics, Inc.（US）
StemCell Technologies Inc.（Canada）
Regenexx（US）
Athersys, Inc.（US）
Mesoblast Limited（Australia）
Cytori Therapeutics, Inc.（US）
OrthoGenics（US）
Panthera Biopartners（UK）
Stemson Therapeutics（US）
Lonza Group AG（Switzerland）
Macopharma（France）
Cure Cell（Turkey）
LifeBankUSA（US）
Biolife Plasma Services, LLC（US）
NexImmune, Inc.（US）

简介目录

Product Code: SQMIG35H2294

Stem Cell Banking Market size was valued at USD 11.65 Billion in 2024 and is poised to grow from USD 13.78 Billion in 2025 to USD 52.88 Billion by 2033, growing at a CAGR of 18.3% during the forecast period (2026-2033).

The stem cell banking market is witnessing significant growth, largely driven by advancements in cryopreservation and the preparation of cell banks. The escalating popularity of monoclonal antibodies and the adoption of stem cell therapies are also key contributors to this trend. Ongoing research in stem cell applications, especially in hematopoietic stem cell transplants for neurodegenerative and cardiovascular diseases, presents vast opportunities. Additionally, tissue banks and biobanks play an essential role in the preservation of adult tissues and stem cells for diverse clinical uses. Innovations in regenerative medicine, such as induced pluripotent stem cells, offer hope for previously untreatable conditions. Furthermore, the rising trend of late parenthood emphasizes the importance of umbilical cord blood banking, as parents seek to secure their infants' stem cells for future medical needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Stem Cell Banking market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Stem Cell Banking Market Segments Analysis

Global Stem Cell Banking Market is segmented by Source, Service Type, Application, and region. Based on Source, the market is segmented into Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS), and Other Stem Cell Sources. Based on Service Type, the market is segmented into Sample Preservation and Storage, Sample Analysis, Sample Processing, and Sample Collection and Transportation. Based on Application, the market is segmented into Personalized Banking Applications, Research Applications, and Clinical Applications. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Stem Cell Banking Market

The stem cell banking market is experiencing a significant shift towards adult stem cells, particularly those derived from bone marrow and adipose tissue. These sources provide greater accessibility and serve as ethically viable alternatives to embryonic stem cells. Additionally, innovations in minimally invasive collection methods, such as needle extraction of bone marrow, are enhancing the overall patient experience, contributing to a growing interest and acceptance of stem cell banking. This combination of accessibility, ethical considerations, and advancements in collection techniques is driving the market forward, fostering increased adoption and integration of stem cell banking services.

Restraints in the Stem Cell Banking Market

The stem cell banking market faces significant challenges due to the ever-evolving regulatory landscape surrounding stem cell research and storage. Governments impose stringent regulations to maintain safety and ethical standards, but the complexity of these requirements poses difficulties for stem cell banking companies. The ongoing changes and uncertainties in regulations can hinder market growth, as companies must remain agile and responsive to adapt to these fluctuations. This dynamic environment can create obstacles, ultimately impacting the ability of market participants to operate effectively and innovate, further complicating their efforts to navigate the intricate regulatory framework.

Market Trends of the Stem Cell Banking Market

The Stem Cell Banking market is experiencing significant growth driven by the rising demand for hematopoietic stem cell transplantation (HSCT), which is increasingly employed in treating blood malignancies and certain genetic disorders. The growing success rates of HSCT procedures underscore the importance of accessible stem cell sources, whether from personal banks or donor registries. As awareness about the benefits of stem cell banking expands among consumers and healthcare providers alike, the need for reliable and readily available stem cell options is surging. This trend is further fueled by advancements in medical technologies and the expansion of research, promising a vibrant future for the sector.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Landscape
Case Study Analysis
Technology Analysis
Supply Chain Analysis
Value Chain Analysis
PESTEL Analysis

Stem Cell Banking Market by Source

Market Overview
Placental Stem Cells (PSCS)
Adipose Tissue-Derived Stem Cells (ADSCS)
Bone Marrow-Derived Stem Cells (BMSCS)
Human Embryo-Derived Stem Cells (HESCS)
Dental Pulp-Derived Stem Cells (DPSCS)
Other Stem Cell Sources

Stem Cell Banking Market by Service Type

Market Overview
Sample Preservation and Storage
Sample Analysis
Sample Processing
Sample Collection and Transportation

Stem Cell Banking Market by Application

Market Overview
Personalized Banking Applications
Research Applications
- Disease Treatment Studies
- Life Science Research
- Drug Discovery
Clinical Applications
- Hematopoietic Disorders
- Autoimmune Disorders
- Other Diseases

Stem Cell Banking Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Cordlife (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cryo-Cell International (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LifeCell International (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemCyte (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Cord Blood (Hong Kong)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smart Cells International (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vita34 (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CryoHoldco (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellerant Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemCell Technologies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenexx (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OrthoGenics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Panthera Biopartners (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stemson Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macopharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cure Cell (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LifeBankUSA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biolife Plasma Services, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NexImmune, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments